

Adeera Levin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/10794975/adeera-levin-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

230
papers

26,113
citations

51
h-index

161
g-index

279
ext. papers

32,024
ext. citations

7.1
avg. IF

6.79
L-index

#	Paper	IF	Citations
230	Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial.. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022 ,	6.9	1
229	The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial.. <i>Diabetes and Metabolism</i> , 2022 , 101331	5.4	0
228	Emerging Role of Clinical Genetics in CKD.. <i>Kidney Medicine</i> , 2022 , 4, 100435	2.8	1
227	Assessing Global Kidney Nutrition Care.. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022 , 17, 38-52	6.9	0
226	Adverse changes in key chronic kidney disease care outcome metrics since onset of the COVID-19 pandemic; experience from an established provincial renal program.. <i>Kidney International</i> , 2022 ,	9.9	
225	Global eHealth capacity: secondary analysis of WHO data on eHealth and implications for kidney care delivery in low-resource settings.. <i>BMJ Open</i> , 2022 , 12, e055658	3	1
224	The rationale for the need to study sodium-glucose co-transport 2 inhibitor usage in peritoneal dialysis patients.. <i>Peritoneal Dialysis International</i> , 2022 , 8968608221096556	2.8	0
223	Protocol for a Multistage Mixed-Methods Evaluation of Multidisciplinary Chronic Kidney Disease Care Quality Following Integration of Virtual and In-Person Care During the COVID-19 Pandemic. <i>Canadian Journal of Kidney Health and Disease</i> , 2022 , 9, 205435812211031	2.3	
222	Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. <i>Journal of Diabetes Research</i> , 2022 , 2022, 1-12	3.9	
221	Anticoagulation for Patients With Atrial Fibrillation and End-Stage Renal Disease on Dialysis: A National Survey. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 924-928	3.8	1
220	The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2021 , 52, 827-836	4.6	3
219	Peritoneal Dialysis Use and Practice Patterns: An International Survey Study. <i>American Journal of Kidney Diseases</i> , 2021 , 77, 315-325	7.4	14
218	Hemodialysis Use and Practice Patterns: An International Survey Study. <i>American Journal of Kidney Diseases</i> , 2021 , 77, 326-335.e1	7.4	5
217	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. <i>American Heart Journal</i> , 2021 , 233, 141-148	4.9	10
216	Slowing Progression in CKD: DAPA CKD and Beyond. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 1117-1119	6.9	3
215	Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada. <i>Kidney International Reports</i> , 2021 , 6, 1130-1140	4.1	0
214	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial. <i>Circulation</i> , 2021 , 143, 1735-1749	16.7	19

213	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Latin America. <i>Kidney International Supplements</i> , 2021 , 11, e35-e46	6.3	2
212	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in South Asia. <i>Kidney International Supplements</i> , 2021 , 11, e97-e105	6.3	2
211	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Eastern and Central Europe. <i>Kidney International Supplements</i> , 2021 , 11, e24-e34	6.3	1
210	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Africa. <i>Kidney International Supplements</i> , 2021 , 11, e11-e23	6.3	2
209	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in the Middle East. <i>Kidney International Supplements</i> , 2021 , 11, e47-e56	6.3	0
208	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Oceania and South East Asia. <i>Kidney International Supplements</i> , 2021 , 11, e86-e96	6.3	3
207	International Society of Nephrology Global Kidney Health Atlas: structures, organization and services for the management of kidney failure in North and East Asia. <i>Kidney International Supplements</i> , 2021 , 11, e77-e85	6.3	3
206	Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. <i>American Journal of Kidney Diseases</i> , 2021 ,	7.4	7
205	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis. <i>Stroke</i> , 2021 , 52, 1545-1556	6.7	11
204	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Newly Independent States and Russia. <i>Kidney International Supplements</i> , 2021 , 11, e57-e65	6.3	1
203	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in North America and the Caribbean. <i>Kidney International Supplements</i> , 2021 , 11, e66-e76	6.3	0
202	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Western Europe. <i>Kidney International Supplements</i> , 2021 , 11, e106-e118	6.3	3
201	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. <i>Kidney International</i> , 2021 , 99, 1280-1295	9.9	18
200	Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey. <i>BMJ Open</i> , 2021 , 11, e047245	3	3
199	Risk of tuberculosis associated with chronic kidney disease: a population-based analysis. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	1
198	Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. <i>CJC Open</i> , 2021 , 3, 965-975	2	5
197	Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. <i>Kidney International</i> , 2021 , 99, 999-1009	10.9	23
196	The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals. <i>Kidney International</i> , 2021 , 99, 551-554	9.9	1

195	Advancing Palliative Care in Patients With CKD: From Ideas to Practice. <i>American Journal of Kidney Diseases</i> , 2021 , 77, 420-426	7.4	3
194	Adapting Nephrology Training Curriculum in the Era of COVID-19. <i>Canadian Journal of Kidney Health and Disease</i> , 2021 , 8, 2054358120988446	2.3	1
193	Maintaining the Uptake of Peritoneal Dialysis During the COVID-19 Pandemic: A Research Letter. <i>Canadian Journal of Kidney Health and Disease</i> , 2021 , 8, 2054358120986265	2.3	4
192	Balancing the Needs of Acute and Maintenance Dialysis Patients during the COVID-19 Pandemic: A Proposed Ethical Framework for Dialysis Allocation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 1122-1130	6.9	5
191	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 384-395	6.9	12
190	Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2. <i>Kidney International Reports</i> , 2021 , 6, 1775-1787	4.1	26
189	The state of the global nephrology workforce: a joint ASN-ERA-EDTA-ISN investigation. <i>Kidney International</i> , 2021 , 100, 995-1000	9.9	2
188	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. <i>European Heart Journal</i> , 2021 ,	9.5	22
187	Validity of different dose reduction criteria for apixaban. <i>American Heart Journal</i> , 2021 , 238, 12-15	4.9	0
186	Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. <i>Kidney International</i> , 2021 , 100, 516-526	9.9	25
185	Standardised Outcomes in Nephrology - Chronic Kidney Disease (SONG-CKD): a protocol for establishing a core outcome set for adults with chronic kidney disease who do not require kidney replacement therapy. <i>Trials</i> , 2021 , 22, 612	2.8	1
184	Assessment of an Interactive Digital Health-Based Self-management Program to Reduce Hospitalizations Among Patients With Multiple Chronic Diseases: A Randomized Clinical Trial.. <i>JAMA Network Open</i> , 2021 , 4, e2140591	10.4	0
183	Assessing the impact of screening, early identification and intervention programmes for chronic kidney disease: protocol for a scoping review.. <i>BMJ Open</i> , 2021 , 11, e053857	3	0
182	Performance of StatSensor Point-of-Care Device for Measuring Creatinine in Patients With Chronic Kidney Disease and Postkidney Transplantation. <i>Canadian Journal of Kidney Health and Disease</i> , 2020 , 7, 2054358120970716	2.3	1
181	Management of Patients With Glomerulonephritis During the COVID-19 Pandemic: Recommendations From the Canadian Society of Nephrology COVID-19 Rapid Response Team. <i>Canadian Journal of Kidney Health and Disease</i> , 2020 , 7, 2054358120968955	2.3	2
180	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 1128-1139	12.7	51
179	Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2020 , 76, 109-120	7.4	4
178	Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. <i>Kidney International</i> , 2020 , 97, 1117-1129	9.9	176

177	Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 1761-1769	4.3	1
176	The role of kidney transplantation as a component of integrated care for chronic kidney disease. <i>Kidney International Supplements</i> , 2020 , 10, e78-e85	6.3	5
175	Development of a framework for minimum and optimal safety and quality standards for hemodialysis and peritoneal dialysis. <i>Kidney International Supplements</i> , 2020 , 10, e55-e62	6.3	5
174	The Global Kidney Health Atlas: Burden and Opportunities to Improve Kidney Health Worldwide. <i>Annals of Nutrition and Metabolism</i> , 2020 , 76 Suppl 1, 25-30	4.5	1
173	Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 15, 1433-1444	6.9	12
172	Availability and Affordability of Kidney Health Laboratory Tests around the Globe. <i>American Journal of Nephrology</i> , 2020 , 51, 959-965	4.6	0
171	Availability, coverage, and scope of health information systems for kidney care across world countries and regions. <i>Nephrology Dialysis Transplantation</i> , 2020 ,	4.3	3
170	Epidemiology of Chronic Kidney Disease Scope of the Problem 2020 , 75-89		2
169	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c . <i>Circulation</i> , 2020 , 141, 407-410	16.7	62
168	High-risk screening for Fabry disease in a Canadian cohort of chronic kidney disease patients. <i>Clinica Chimica Acta</i> , 2020 , 501, 234-240	6.2	6
167	Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 903-914	18.1	34
166	Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Analysis from the CREDENCE Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 2925-2936	12.7	30
165	International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , 2020 , 98, 849-859	9.9	19
164	International perspectives on patient involvement in clinical trials in nephrology. <i>Kidney International</i> , 2020 , 98, 566-571	9.9	9
163	Effects of Canagliflozin in Patients with Baseline eGFR . <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 15, 1705-1714	6.9	30
162	Alport Syndrome Classification and Management. <i>Kidney Medicine</i> , 2020 , 2, 639-649	2.8	12
161	A Provincial Survey of the Contemporary Management of Autosomal Dominant Polycystic Kidney Disease. <i>Canadian Journal of Kidney Health and Disease</i> , 2020 , 7, 2054358120948294	2.3	2
160	The CSN COVID-19 Rapid Response Program. <i>Canadian Journal of Kidney Health and Disease</i> , 2020 , 7, 2054358120949110	2.3	1

159	Predicting kidney failure risk after acute kidney injury among people receiving nephrology clinic care. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 836-845	4.3	8
158	Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. <i>American Journal of Kidney Diseases</i> , 2020 , 73, 84-104	7.4	124
157	Availability, Accessibility, and Quality of Conservative Kidney Management Worldwide. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 16, 79-87	6.9	7
156	SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 845-854	18.1	335
155	Capacity of Kidney Care in Canada: Identifying Barriers and Opportunities. <i>Canadian Journal of Kidney Health and Disease</i> , 2019 , 6, 2054358119870540	2.3	2
154	Prospective Biopsy-Based Study of CKD of Unknown Etiology in Sri Lanka. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 224-232	6.9	15
153	CKD Hotspots: Challenges and Areas of Opportunity. <i>Seminars in Nephrology</i> , 2019 , 39, 308-314	4.8	15
152	CT of Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: Accuracy, Reproducibility, and Radiation Dose. <i>Radiology</i> , 2019 , 291, 660-667	20.5	3
151	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019 , 380, 2295-2306	59.2	2060
150	Renal pathology practice globally: identifying needs and meeting the challenge. <i>Kidney International</i> , 2019 , 96, 258-261	9.9	2
149	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019 , 140, 739-750	16.7	140
148	Glomerular Filtration Rate-Specific Cutoffs Can Refine the Prognostic Value of Circulating Cardiac Biomarkers in Advanced Chronic Kidney Disease. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 1106-1113	3.8	2
147	GFR-Specific versus GFR-Agnostic Cutoffs for Parathyroid Hormone and Fibroblast Growth Factor-23 in Advanced Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2019 , 50, 105-114	4.6	5
146	Multidisciplinary Chronic Kidney Disease Clinic Practices: A Scoping Review. <i>Canadian Journal of Kidney Health and Disease</i> , 2019 , 6, 2054358119882667	2.3	12
145	Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. <i>BMJ, The</i> , 2019 , 367, l5873	5.9	55
144	The Role of the Chronic Kidney Disease Clinic and Multidisciplinary Team Care 2019 , 121-135.e6		0
143	Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. <i>American Journal of Kidney Diseases</i> , 2019 , 73, 206-217	7.4	25
142	Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis. <i>American Journal of Kidney Diseases</i> , 2019 , 73, 39-50	7.4	6

141	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 257-264	4.3	6
140	A Peculiar Case of Paraproteinemia and Elevated Creatinine. <i>American Journal of Kidney Diseases</i> , 2018 , 71, A14-A15	7.4	4
139	What We Do and Do Not Know about Women and Kidney Diseases; Questions Unanswered and Answers Unquestioned: Reflection on World Kidney Day and International Woman's Day. <i>Blood Purification</i> , 2018 , 45, 364-375	3.1	5
138	Global challenges in kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 371-372	4.3	3
137	Risk Factors for Prognosis in Patients With Severely Decreased GFR. <i>Kidney International Reports</i> , 2018 , 3, 625-637	4.1	28
136	What we do and do not know about women and kidney diseases; questions unanswered and answers unquestioned: Reflection on World Kidney Day and International Woman's Day. <i>Nefrologia</i> , 2018 , 38, 114-124	0.4	
135	Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from aKidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2018 , 93, 1281-1292	9.9	41
134	What We Do and Do Not Know about Women and Kidney Diseases; Questions Unanswered and Answers Unquestioned: Reflection on World Kidney Day and International Women's Day. <i>Nephron</i> , 2018 , 138, 249-260	3.3	3
133	Global nephrology workforce: gaps and opportunities toward a sustainable kidney care system. <i>Kidney International Supplements</i> , 2018 , 8, 52-63	6.3	64
132	Global access of patients with kidney disease to health technologies and medications: findings from the Global Kidney Health Atlas project. <i>Kidney International Supplements</i> , 2018 , 8, 64-73	6.3	39
131	Global coverage of health information systems for kidney disease: availability, challenges, and opportunities for development. <i>Kidney International Supplements</i> , 2018 , 8, 74-81	6.3	17
130	Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology. <i>Kidney International Supplements</i> , 2018 , 8, 82-89	6.3	9
129	Guidelines, policies, and barriers to kidney care: findings from a global survey. <i>Kidney International Supplements</i> , 2018 , 8, 30-40	6.3	13
128	Global overview of health systems oversight and financing for kidney care. <i>Kidney International Supplements</i> , 2018 , 8, 41-51	6.3	30
127	Women and kidney disease: reflections on World Kidney Day 2018. <i>CKJ: Clinical Kidney Journal</i> , 2018 , 11, 7-11	4.5	10
126	Women and Kidney Disease: Reflections on World Kidney Day 2018. <i>Journal of Hypertension</i> , 2018 , 36, 705-708	1.9	1
125	Effectiveness and Cost of Weekly Recombinant Tissue Plasminogen Activator Hemodialysis Catheter Locking Solution. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018 , 13, 429-435	6.9	6
124	What we do and do not know about women and kidney diseases; questions unanswered and answers unquestioned: Reflection on World Kidney Day and International Woman's Day. <i>Nefrologia</i> , 2018 , 38, 114-124	1.5	0

123	External validation and clinical utility of a prediction model for 6-month mortality in patients undergoing hemodialysis for end-stage kidney disease. <i>Palliative Medicine</i> , 2018 , 32, 395-403	5.5	8
122	Long-term patient and kidney survival after coronary artery bypass grafting, percutaneous coronary intervention, or medical therapy for patients with chronic kidney disease: a propensity-matched cohort study. <i>Coronary Artery Disease</i> , 2018 , 29, 8-16	1.4	8
121	Nephrology in the Oceania-South East Asia region: perspectives and challenges. <i>Kidney International</i> , 2018 , 94, 465-470	9.9	4
120	Variability in Non-Vitamin K Antagonist Oral Anticoagulants Dose Adjustment in Atrial Fibrillation Patients With Renal Dysfunction: The Influence of Renal Function Estimation Formulae. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1010-1018	3.8	23
119	Cardiovascular Outcomes Reported in Hemodialysis Trials. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2802-2810	15.1	14
118	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. <i>Kidney International</i> , 2018 , 93, 1000-1007	9.9	21
117	What we do and do not know about women and kidney diseases; questions unanswered and answers unquestioned: Reflection on World Kidney Day and International Woman's Day. <i>Nephrology @ Point of Care</i> , 2018 , 4, 205930071775305	0.5	
116	FO068KIDNEY FAILURE AFTER AKI AMONG PEOPLE UNDER NEPHROLOGY CLINIC CARE: A PROVINCEWIDE COHORT STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, i47-i48	4.3	
115	Pregnancy in Chronic Kidney Disease: Need for Higher Awareness. A Pragmatic Review Focused on What Could Be Improved in the Different CKD Stages and Phases. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	18
114	Acute Kidney Injury in Pregnancy: The Need for Higher Awareness. A Pragmatic Review Focused on What Could Be Improved in the Prevention and Care of Pregnancy-Related AKI, in the Year Dedicated to Women and Kidney Diseases. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	12
113	Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20 Suppl 3, 24-29	6.7	7
112	Women and Kidney Disease: Reflections on World Kidney Day 2018. <i>Nephrology Nursing Journal</i> , 2018 , 45, 65-70	0.4	
111	The KRESCENT Program (2005-2015): An Evaluation of the State of Kidney Research Training in Canada. <i>Canadian Journal of Kidney Health and Disease</i> , 2017 , 4, 2054358117693354	2.3	2
110	Assessment of Global Kidney Health Care Status. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 1864-1881	27.4	196
109	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. <i>Lancet, The</i> , 2017 , 390, 1888-1917	40	419
108	Evaluation of a 12-Month Pilot of Long-Term and Temporary Assisted Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2017 , 37, 307-313	2.8	23
107	Global Kidney Health Atlas (GKHA): design and methods. <i>Kidney International Supplements</i> , 2017 , 7, 145-153	15.3	25
106	Daily Intake of Grape Powder Prevents the Progression of Kidney Disease in Obese Type 2 Diabetic ZSF1 Rats. <i>Nutrients</i> , 2017 , 9,	6.7	13

105	A Rebuttal to "The CKD Classification System in the Precision Medicine Era". <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 1711-1713	6.9	2
104	Chronic kidney disease. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17088	51.1	261
103	Cardiovascular risk is similar in patients with glomerulonephritis compared to other types of chronic kidney disease: a matched cohort study. <i>BMC Nephrology</i> , 2017 , 18, 95	2.7	3
102	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDESCENCE) Study Rationale, Design, and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2017 , 46, 462-472	4.6	149
101	International Network of Chronic Kidney Disease cohort studies (iNET-CKD): a global network of chronic kidney disease cohorts. <i>BMC Nephrology</i> , 2016 , 17, 121	2.7	34
100	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016 , 68, 371-80	7.4	37
99	Past Decline Versus Current eGFR and Subsequent ESRD Risk. <i>Journal of the American Society of Nephrology: JASN</i> , 2016 , 27, 2447-55	12.7	52
98	The Lancet Kidney Campaign: an opportunity for partnerships. <i>Lancet, The</i> , 2016 , 387, 1038-1039	4.0	2
97	Predicting Progression in CKD: Perspectives and Precautions. <i>American Journal of Kidney Diseases</i> , 2016 , 67, 779-86	7.4	11
96	The BBlocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2016 , 67, 902-11	7.4	26
95	Perspectives on optimizing care of patients in multidisciplinary chronic kidney disease clinics. <i>Canadian Journal of Kidney Health and Disease</i> , 2016 , 3, 32	2.3	10
94	Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events. <i>Kidney International</i> , 2016 , 89, 1144-1152	9.9	105
93	Tuberculosis and chronic kidney disease: an emerging global syndemic. <i>Kidney International</i> , 2016 , 90, 34-40	9.9	62
92	Recognizing IgG4-related tubulointerstitial nephritis. <i>Canadian Journal of Kidney Health and Disease</i> , 2016 , 3, 34	2.3	10
91	Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney disease and mortality. <i>Kidney International</i> , 2016 , 90, 897-904	9.9	36
90	Time to revisit the problem of CIN? The low incidence of acute kidney injury with and without contrast in hospitalized patients: an observational cohort study. <i>Canadian Journal of Kidney Health and Disease</i> , 2015 , 2, 38	2.3	11
89	Effective CKD care in European countries: challenges and opportunities for health policy. <i>American Journal of Kidney Diseases</i> , 2015 , 65, 15-25	7.4	50
88	High-performance information search filters for CKD content in PubMed, Ovid MEDLINE, and EMBASE. <i>American Journal of Kidney Diseases</i> , 2015 , 65, 26-32	7.4	9

87	Epidemiology of Chronic Kidney Disease: Scope of the Problem 2015 , 57-68		1
86	Perceptions of prognostic risks in chronic kidney disease: a national survey. <i>Canadian Journal of Kidney Health and Disease</i> , 2015 , 2, 53	2.3	10
85	A Fine Balance: Developing Clinical Practice Guidelines in Areas Where Evidence is Lacking. <i>Seminars in Dialysis</i> , 2015 , 28, 654-6	2.5	4
84	Integrating guidelines, CKD, multimorbidity, and older adults. <i>American Journal of Kidney Diseases</i> , 2015 , 65, 494-501	7.4	15
83	Transplant commercialism and organ trafficking: the Declaration of Istanbul with special relevance to disadvantaged populations living with kidney disease. <i>Clinical Nephrology</i> , 2015 , 83, 85-9	2.1	3
82	Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2014 , 64, 40-8	7.4	46
81	Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. <i>Kidney International</i> , 2014 , 85, 49-61	9.9	375
80	The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists. <i>CKJ: Clinical Kidney Journal</i> , 2014 , 7, 538-45	4.5	14
79	Chronic kidney disease and support provided by home care services: a systematic review. <i>BMC Nephrology</i> , 2014 , 15, 118	2.7	16
78	Fluid balance, change in serum creatinine and urine output as markers of acute kidney injury post cardiac surgery: an observational study. <i>Canadian Journal of Kidney Health and Disease</i> , 2014 , 1, 19	2.3	8
77	The Canadian Society of Nephrology methods in developing and adapting clinical practice guidelines: a review. <i>Canadian Journal of Kidney Health and Disease</i> , 2014 , 1, 5	2.3	4
76	CKD stage at nephrology referral and factors influencing the risks of ESRD and death. <i>American Journal of Kidney Diseases</i> , 2014 , 63, 928-36	7.4	30
75	Interventions for promoting adherence to fluid intake and dietary salt restriction in people with end-stage kidney disease. <i>The Cochrane Library</i> , 2014 ,	5.2	2
74	The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014 , 9, 914-9 ^{6.9}		12
73	Geographic and facility-level variation in the use of peritoneal dialysis in Canada: a cohort study. <i>CMAJ Open</i> , 2014 , 2, E36-44	2.5	16
72	Clinical trials: ISN-ACCTS: global initiatives to improve clinical research. <i>Nature Reviews Nephrology</i> , 2014 , 10, 426-7	14.9	2
71	Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. <i>Kidney International</i> , 2014 , 86, 819-27	9.9	52
70	Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 1037-47	4.3	41

69	Effects of lowering LDL cholesterol on progression of kidney disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 1825-33	12.7	108
68	Remembering the forgotten non-communicable diseases. <i>BMC Medicine</i> , 2014 , 12, 200	11.4	51
67	Cohort profile: Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT). <i>BMC Nephrology</i> , 2013 , 14, 121	2.7	48
66	The British Columbia Nephrologists' Access Study (BCNAS) - a prospective, health services interventional study to develop waiting time benchmarks and reduce wait times for out-patient nephrology consultations. <i>BMC Nephrology</i> , 2013 , 14, 182	2.7	9
65	Evolving importance of kidney disease: from subspecialty to global health burden. <i>Lancet, The</i> , 2013 , 382, 158-69	40	624
64	Targets, trends, excesses, and deficiencies: refocusing clinical investigation to improve patient outcomes. <i>Kidney International</i> , 2013 , 83, 1001-9	9.9	11
63	Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. <i>BMJ, The</i> , 2013 , 346, f324	5.9	224
62	Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. <i>Annals of Internal Medicine</i> , 2013 , 158, 825-30	8	1395
61	Activity-based funding model provides foundation for province-wide best practices in renal care. <i>Healthcare Quarterly</i> , 2013 , 16, 49-54		7
60	Biomarkers in native and transplant kidneys: opportunities to improve prediction of outcomes in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2012 , 21, 619-27	3.5	10
59	Age and association of kidney measures with mortality and end-stage renal disease. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 2349-60	27.4	371
58	Towards rational approaches of health care utilization in complex patients: an exploratory randomized trial comparing a novel combined clinic to multiple specialty clinics in patients with renal disease-cardiovascular disease-diabetes. <i>Nephrology Dialysis Transplantation</i> , 2012 , 27 Suppl 3, iii104-10	4.3	20
57	Does an association exist between pseudoexfoliation syndrome and chronic kidney disease?. <i>Journal of Glaucoma</i> , 2012 , 21, 562-6	2.1	5
56	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <i>Lancet, The</i> , 2011 , 377, 2181-92	40	1627
55	Early detection of CKD: the benefits, limitations and effects on prognosis. <i>Nature Reviews Nephrology</i> , 2011 , 7, 446-57	14.9	51
54	A predictive model for progression of chronic kidney disease to kidney failure. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1553-9	27.4	625
53	Nondialysis chronic kidney disease in 2011: Progression, prediction, populations and possibilities. <i>Nature Reviews Nephrology</i> , 2011 , 8, 70-2	14.9	1
52	Evaluation of creatinine-based formulas in dosing adjustment of cancer drugs other than carboplatin. <i>Journal of Oncology Pharmacy Practice</i> , 2010 , 16, 113-9	1.7	16

51	Incidence and outcomes of acute kidney injury in a referred chronic kidney disease cohort. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 2203-9	4.3	71
50	The Role of the Chronic Kidney Disease Clinic 2010 , 75-86		1
49	TREAT: Implications for guideline updates and clinical care. <i>American Journal of Kidney Diseases</i> , 2010 , 55, 984-7	7.4	2
48	Guidelines in nephrology: a new era of stimulating best care and best science. <i>Nephrology News & Issues</i> , 2009 , 23, 45-6		
47	Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. <i>American Journal of Kidney Diseases</i> , 2008 , 52, 661-71	7.4	201
46	KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD. <i>American Journal of Kidney Diseases</i> , 2008 , 52, 811-25	7.4	37
45	Regional implementation of creatinine measurement standardization. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 164-9	12.7	30
44	Anemia as a risk factor for kidney function decline in individuals with heart failure. <i>American Journal of Cardiology</i> , 2007 , 99, 1137-42	3	36
43	Conservative outpatient renoprotective protocol in patients with low GFR undergoing contrast angiography: a case series. <i>Clinical and Experimental Nephrology</i> , 2007 , 11, 209-213	2.5	14
42	Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 309-12	4.3	34
41	Towards a Better Understanding of Cardiac and Vascular Disease in Patients with Chronic Kidney Disease. <i>Current Cardiology Reviews</i> , 2007 , 3, 105-109	2.4	
40	N-acetylcysteine reduces urinary albumin excretion following contrast administration: evidence of biological effect. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 2520-4	4.3	20
39	Epoetin trials: randomised controlled trials don't always mimic observational data. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 684-6	4.3	6
38	Appraisal of evidence and control of bias in the kidney disease outcomes quality initiative guideline development process. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007 , 2, 8-10	6.9	8
37	The treatment of anemia in chronic kidney disease: understandings in 2006. <i>Current Opinion in Nephrology and Hypertension</i> , 2007 , 16, 267-71	3.5	16
36	Kidneys, hearts, hormones and immunomodulators: integrated understandings. <i>Blood Purification</i> , 2006 , 24, 46-50	3.1	7
35	Haemoglobin at time of referral prior to dialysis predicts survival: an association of haemoglobin with long-term outcomes. <i>Nephrology Dialysis Transplantation</i> , 2006 , 21, 370-7	4.3	57
34	Response to Letter Regarding Article by Khan et al, Prognostic Value of Troponin T and I Among Asymptomatic Patients With End-Stage Renal Disease: A Meta-Analysis <i>Circulation</i> , 2006 , 113,	16.7	1

33	Anemia and the heart in chronic kidney disease. <i>Seminars in Nephrology</i> , 2006 , 26, 290-5	4.8	15
32	Analysis of cardiovascular disease and kidney outcomes in multidisciplinary chronic kidney disease clinics: complex disease requires complex care models. <i>Current Opinion in Nephrology and Hypertension</i> , 2006 , 15, 61-6	3.5	20
31	A new initiative in nephrology: 'Kidney disease: improving global outcomes'. <i>Contributions To Nephrology</i> , 2005 , 149, 90-99	1.6	11
30	Multiple risk factor intervention in chronic kidney disease: management of cardiac disease in chronic kidney disease patients. <i>Medical Clinics of North America</i> , 2005 , 89, 511-23	7	9
29	Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). <i>Kidney International</i> , 2005 , 67, 2089-100	9.9	2083
28	Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease?. <i>Kidney International</i> , 2005 , 68, 1973-81	9.9	118
27	The need for optimal and coordinated management of CKD. <i>Kidney International</i> , 2005 , S7-10	9.9	18
26	Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. <i>American Journal of Kidney Diseases</i> , 2005 , 46, 799-811	7.4	157
25	Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 148-56	12.7	175
24	Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 1640-7	12.7	61
23	The burden of kidney disease: improving global outcomes. <i>Kidney International</i> , 2004 , 66, 1310-4	9.9	278
22	Anaemia, cardiovascular disease and kidney disease: integrating new knowledge in 2002. <i>Current Opinion in Nephrology and Hypertension</i> , 2003 , 12, 133-8	3.5	15
21	National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. <i>Annals of Internal Medicine</i> , 2003 , 139, 137-47	8	3126
20	National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. <i>Pediatrics</i> , 2003 , 111, 1416-21	7.4	457
19	Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. <i>Seminars in Dialysis</i> , 2003 , 16, 101-5	2.5	183
18	Nephrology: 4. Strategies for the care of adults with chronic kidney disease. <i>Cmaj</i> , 2003 , 168, 1553-60	3.5	7
17	Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. <i>Kidney International</i> , 2002 , 35-8	9.9	82
16	Should hemoglobin be normalized in patients with chronic kidney disease?. <i>Seminars in Dialysis</i> , 2002 , 15, 8-13	2.5	17

15	Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). <i>Archives of Internal Medicine</i> , 2002 , 162, 1401-8		482
14	The role of anaemia in the genesis of cardiac abnormalities in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2002 , 17, 207-10	4-3	10
13	Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency. <i>Nephrology Dialysis Transplantation</i> , 2002 , 17, 1426-33	4-3	33
12	Cardiovascular disease and the kidney. Tracking a killer in chronic kidney disease. <i>Postgraduate Medicine</i> , 2002 , 111, 53-60	3-7	31
11	The relationship of haemoglobin level and survival: direct or indirect effects?. <i>Nephrology Dialysis Transplantation</i> , 2002 , 17 Suppl 5, 8-13	4-3	19
10	When does anemia impact the heart in chronic kidney disease? 2002 , 37-47		
9	Cardiovascular Disease in Patients with Chronic Kidney Disease: The Causes and Effects 2002 , 29-38		
8	Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. <i>American Journal of Kidney Diseases</i> , 2001 , 38, 1398-407	7-4	167
7	Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. <i>American Journal of Kidney Diseases</i> , 2001 , 37, 484-489	7-4	163
6	Post-transplant diabetic ketoacidosis - A possible consequence of immunosuppression with calcineurin inhibiting agents: A case series. <i>Transplant International</i> , 2000 , 13, 69-72	3	14
5	Defining a renal anemia management period. <i>American Journal of Kidney Diseases</i> , 2000 , 36, S13-23	7-4	31
4	Cardiovascular disease in chronic renal insufficiency. <i>American Journal of Kidney Diseases</i> , 2000 , 36, S24-30	4	105
3	Post-transplant diabetic ketoacidosis--a possible consequence of immunosuppression with calcineurin inhibiting agents: a case series. <i>Transplant International</i> , 2000 , 13, 69-72	3	4
2	Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. <i>American Journal of Kidney Diseases</i> , 1999 , 34, 125-34	7-4	650
1	Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. <i>American Journal of Kidney Diseases</i> , 1996 , 27, 347-54	7-4	548